Shopping Cart 0
Cart Subtotal
USD 0

Apexigen Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Apexigen Inc (Apexigen) is a clinical-stage biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of cancer. The company's lead immune oncology program APX005M, is a humanized monoclonal antibody that stimulates cancer specific T-cell responses. It also provides other immune oncology drug candidates that are in pre clinical stage of development. The company develops pipeline products using its APXiMAB, a proprietary antibody discovery platform. The company works in strategic collaboration with various pharmaceutical companies to develop drugs for the treatment of cancer and inflammation, among others. Apexigen is headquartered in San Carlos, California, the US.

Apexigen Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Apexigen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Apexigen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Apexigen Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Apexigen Raises USD15 Million in Series B Venture Financing 10

Apexigen Raises USD58 Million in Series C Venture Financing 11

Apexigen Raises USD 20 Million In Series A1 Financing 12

Apexigen Raises USD 15 Million In Venture Financing 14

Partnerships 15

Apexigen and Yale Cancer Center Enter into Clinical Collaboration Agreement 15

Apexigen Enters into Agreement with Pediatric Brain Tumor Consortium 16

Apexigen Enters into Agreement with University of California San Francisco 17

Neon Therapeutics Enters into Agreement with Apexigen 18

Bristol-Myers Squibb Enters into Agreement with Apexigen 19

Licensing Agreements 20

Apexigen Enters Into Licensing Agreement With Gansu Duyiwei Biological Pharma For APX004 20

Asset Transactions 21

3SBio Acquires Anti-TNF Monoclonal Antibody Technology from Apexigen 21

Apexigen Inc-Key Competitors 22

Apexigen Inc-Key Employees 23

Apexigen Inc-Locations And Subsidiaries 24

Head Office 24

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25


List Of Figure

List of Figures

Apexigen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Apexigen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Apexigen Inc, Pharmaceuticals & Healthcare, Key Facts 2

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Apexigen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Apexigen Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Apexigen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Apexigen Raises USD15 Million in Series B Venture Financing 10

Apexigen Raises USD58 Million in Series C Venture Financing 11

Apexigen Raises USD 20 Million In Series A1 Financing 12

Apexigen Raises USD 15 Million In Venture Financing 14

Apexigen and Yale Cancer Center Enter into Clinical Collaboration Agreement 15

Apexigen Enters into Agreement with Pediatric Brain Tumor Consortium 16

Apexigen Enters into Agreement with University of California San Francisco 17

Neon Therapeutics Enters into Agreement with Apexigen 18

Bristol-Myers Squibb Enters into Agreement with Apexigen 19

Apexigen Enters Into Licensing Agreement With Gansu Duyiwei Biological Pharma For APX004 20

3SBio Acquires Anti-TNF Monoclonal Antibody Technology from Apexigen 21

Apexigen Inc, Key Competitors 22

Apexigen Inc, Key Employees 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Apexigen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Apexigen Inc (Apexigen) is a clinical-stage biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of cancer. The company's lead immune oncology program APX005M, is a humanized monoclonal antibody that stimulates cancer specific T-cell responses. It also provides other immune oncology drug candidates that are in pre clinical stage of development. The company develops pipeline products using its APXiMAB, a proprietary antibody discovery platform. The company works in strategic collaboration with various pharmaceutical companies to develop drugs for the treatment of cancer and inflammation, among others. Apexigen is headquartered in San Carlos, California, the US.

Apexigen Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Apexigen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Apexigen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Apexigen Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Apexigen Raises USD15 Million in Series B Venture Financing 10

Apexigen Raises USD58 Million in Series C Venture Financing 11

Apexigen Raises USD 20 Million In Series A1 Financing 12

Apexigen Raises USD 15 Million In Venture Financing 14

Partnerships 15

Apexigen and Yale Cancer Center Enter into Clinical Collaboration Agreement 15

Apexigen Enters into Agreement with Pediatric Brain Tumor Consortium 16

Apexigen Enters into Agreement with University of California San Francisco 17

Neon Therapeutics Enters into Agreement with Apexigen 18

Bristol-Myers Squibb Enters into Agreement with Apexigen 19

Licensing Agreements 20

Apexigen Enters Into Licensing Agreement With Gansu Duyiwei Biological Pharma For APX004 20

Asset Transactions 21

3SBio Acquires Anti-TNF Monoclonal Antibody Technology from Apexigen 21

Apexigen Inc-Key Competitors 22

Apexigen Inc-Key Employees 23

Apexigen Inc-Locations And Subsidiaries 24

Head Office 24

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25


List Of Figure

List of Figures

Apexigen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Apexigen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Apexigen Inc, Pharmaceuticals & Healthcare, Key Facts 2

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Apexigen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Apexigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Apexigen Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Apexigen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Apexigen Raises USD15 Million in Series B Venture Financing 10

Apexigen Raises USD58 Million in Series C Venture Financing 11

Apexigen Raises USD 20 Million In Series A1 Financing 12

Apexigen Raises USD 15 Million In Venture Financing 14

Apexigen and Yale Cancer Center Enter into Clinical Collaboration Agreement 15

Apexigen Enters into Agreement with Pediatric Brain Tumor Consortium 16

Apexigen Enters into Agreement with University of California San Francisco 17

Neon Therapeutics Enters into Agreement with Apexigen 18

Bristol-Myers Squibb Enters into Agreement with Apexigen 19

Apexigen Enters Into Licensing Agreement With Gansu Duyiwei Biological Pharma For APX004 20

3SBio Acquires Anti-TNF Monoclonal Antibody Technology from Apexigen 21

Apexigen Inc, Key Competitors 22

Apexigen Inc, Key Employees 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Apexigen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.